Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 2
1994 1
1996 4
1997 5
1998 5
1999 9
2000 26
2001 27
2002 47
2003 76
2004 116
2005 109
2006 135
2007 134
2008 204
2009 149
2010 150
2011 137
2012 124
2013 99
2014 93
2015 83
2016 63
2017 61
2018 47
2019 49
2020 32
2021 46
2022 22
2023 20
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

1,868 results

Results by year

Filters applied: . Clear all
Page 1
Recombinant FVIIa.
Hedner U. Hedner U. Vox Sang. 2004 Jul;87 Suppl 2:25-8. doi: 10.1111/j.1741-6892.2004.00449.x. Vox Sang. 2004. PMID: 15209873 Review. No abstract available.
First 20 years with recombinant FVIIa (NovoSeven).
Hedner U, Lee CA. Hedner U, et al. Haemophilia. 2011 Jan;17(1):e172-82. doi: 10.1111/j.1365-2516.2010.02352.x. Haemophilia. 2011. PMID: 20609014 Review.
This review describes the background for the development of recombinant FVIIa (rFVIIa; NovoSeven) for use in haemophilic patients with inhibitors. ...
This review describes the background for the development of recombinant FVIIa (rFVIIa; NovoSeven) for use in haemophilic patie …
Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B, Geldziler B, Bjerre J, Seremetis S. Goldstein B, et al. Transfus Apher Sci. 2008 Feb;38(1):25-32. doi: 10.1016/j.transci.2007.12.002. Epub 2008 Feb 11. Transfus Apher Sci. 2008. PMID: 18267372 Review.
We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophilia A and B with inhibitors, focusing on registry data and recent clinical trial results. Based on this review of the literature, we conclude …
We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophil …
Mechanism of action, development and clinical experience of recombinant FVIIa.
Hedner U. Hedner U. J Biotechnol. 2006 Aug 5;124(4):747-57. doi: 10.1016/j.jbiotec.2006.03.042. Epub 2006 May 12. J Biotechnol. 2006. PMID: 16697480 Review.
Recombinant FVIIa has been developed for treatment of bleedings in hemophilia patients with inhibitors, and has been found to induce hemostasis even during major surgery such as major orthopedic surgery. Recombinant FVIIa is being produced in BHK cell …
Recombinant FVIIa has been developed for treatment of bleedings in hemophilia patients with inhibitors, and has been found to …
Recombinant FVIIa in children with liver disease.
Pettersson M, Fischler B, Petrini P, Schulman S, Nemeth A. Pettersson M, et al. Thromb Res. 2005;116(3):185-97. doi: 10.1016/j.thromres.2004.11.020. Epub 2005 Jan 6. Thromb Res. 2005. PMID: 15935827 Clinical Trial.
1,868 results